^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    4d
    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Alexander B Olawaiye, MD | Trial completion date: Mar 2033 --> Dec 2034 | Trial primary completion date: Dec 2031 --> Nov 2033
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Talzenna (talazoparib) • ZEN-3694
    6d
    Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=48, Recruiting, Ronald Buckanovich | Trial completion date: Mar 2033 --> Sep 2032 | Trial primary completion date: Mar 2031 --> Aug 2031
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • Erivedge (vismodegib)
    8d
    FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (clinicaltrials.gov)
    P3, N=1630, Recruiting, Eli Lilly and Company | N=1080 --> 1630 | Trial primary completion date: Apr 2028 --> Nov 2028
    Enrollment change • Trial primary completion date • Platinum sensitive • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • sofetabart mipitecan (LY4170156)
    9d
    mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (clinicaltrials.gov)
    P1, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)
    12d
    Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=46, Completed, Genelux Corporation | Phase classification: P1b --> P1/2
    Phase classification • IO biomarker
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • carboplatin • albumin-bound paclitaxel • olvimulogene nanivacirepvec (GL-ONC1)
    16d
    GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    17d
    Tubal epithelial alterations: evolving concepts. (PubMed, J Gynecol Oncol)
    These findings underscore the complexity and heterogeneity of tubal epithelial alterations and suggest that not all lesions follow a linear tumorigenic sequence. Continued integration of morphological, molecular, and spatial analyses will be essential for refining our understanding of tubal pathology and its contribution to gynecological carcinogenesis.
    Review • Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    21d
    SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
    P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    21d
    GLORIOSA: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (clinicaltrials.gov)
    P3, N=520, Active, not recruiting, AbbVie | Trial primary completion date: May 2032 --> Apr 2027
    Trial primary completion date • Platinum sensitive
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    21d
    A Study of Lorigerlimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=80, Recruiting, MacroGenics | N=60 --> 80 | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Jul 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    lorigerlimab (MGD019)
    23d
    DUAL-OV-CAR-NK: Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    FOLR1 ( Folate receptor alpha ) • MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    cyclophosphamide • fludarabine IV
    26d
    Association of SNHG17/CDKN2B-AS1 polymorphisms with salpingitis and fallopian tube carcinoma susceptibility in the Chinese Han population. (PubMed, Gynecol Pelvic Med)
    However, no significant associations were found between these SNPs and salpingitis susceptibility. Given the genetic heterogeneity among Han Chinese populations across different regions, these findings from a single center in Sichuan should be validated in multi-regional cohorts to generalize their applicability.
    Journal
    |
    CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SNHG17 (Small Nucleolar RNA Host Gene 17)